|
[1] JIMNEZ-RIVERA C,LING SC,AHMED N,et al. Incidence and characteristics of autoimmune hepatitis[J]. Pediatrics,2015,136(5):e1237-1248.
|
|
[2] MIELI-VERGANI G,VERGANI D. Budesonide for juvenile autoimmune hepatitis? Not yet[J]. J Pediatr,2013,163(5):1246-1248.
|
|
[3] MIELI-VERGANI G,VERGANI D,BAUMANN U,et al. Diagnosis and management of pediatric autoimmune liver disease:ESPGHAN hepatology committee position statement[J]. J Pediatr Gastroenterol Nutr,2018,66(2):345-360.
|
|
[4] ALVAREZ F,BERG PA,BIANCHI FB,et al. International autoimmune hepatitis group report:Review of criteria for diagnosis of autoimmune hepatitis[J]. J Hepatol,1999,31(5):929-938.
|
|
[5] HENNES EM,ZENIYA M,CZAJA AJ,et al. Simplified criteria for the diagnosis of autoimmune hepatitis[J]. Hepatology,2008,48(1):169-176.
|
|
[6] HIEJIMA E,KOMATSU H,SOGO T,et al. Utility of simplified criteria for the diagnosis of autoimmune hepatitis in children[J]. J Pediatr Gastroenterol Nutr,2011,52(4):470-473.
|
|
[7] SEBODE M,HARTL J,VERGANI D,et al. Autoimmune hepatitis:From current knowledge and clinical practice to future research agenda[J]. Liver Int,2018,38(1):15-22.
|
|
[8] LIWINSKI T,SCHRAMM C. Autoimmune hepatitis-update on clinical management in 2017[J]. Clin Res Hepatol Gastroenterol,2017,41(6):617-625.
|
|
[9] CAO LL,ZHANG M,ZHU SS,et al. Clinical and pathological characteristics and outcome of 46 children with autoimmune hepatitis[J]. Chin J Pediatr,2019,57(1):40-45.(in Chinese)曹丽丽，张敏，朱世殊，等．儿童自身免疫性肝炎46例临床病理特点及疗效分析[J]．中华儿科杂志，2019,57(1):40-45.
|
|
[10] BAVEN-PRONK M,BIEWENGA M,van SILFHOUT JJ,et al.Role of age in presentation,response to therapy and outcome of autoimmune hepatitis[J]. Clin Transl Gastroenterol,2018,9(6):165.
|
|
[11] FOGEL R,COMERFORD M,CHILUKURI P,et al. Extrahepatic autoimmune diseases are prevalent in autoimmune hepatitis patients and their first-degree relatives:Survey study[J]. Interact J Med Res,2018,7(2):e18.
|
|
[12] GUO L,ZHOU L,ZHANG N,et al. Extrahepatic autoimmune diseases in patients with autoimmune liver diseases:A phenomenon neglected by gastroenterologists[J]. Gastroenterol Res Pract,2017,2017:2376231.
|
|
[13] FERRE EM,ROSE SR,ROSENZWEIG SD,et al. Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy[J]. JCI Insight,2016,1(13):e88782.
|
|
[14] TERZIROLI BERETTA-PICCOLI B,MIELI-VERGANI G,VERGANI D. The clinical usage and definition of autoantibodies in immune-mediated liver disease:A comprehensive overview[J]. J Autoimmun,2018,95:144-158.
|
|
[15] VILLALTA D,GIROLAMI E,ALESSIO MG,et al. Autoantibody profiling in a cohort of pediatric and adult patients with autoimmune hepatitis[J]. J Clin Lab Anal,2016,30(1):41-46.
|
|
[16] VERGANI D,ALVAREZ F,BIANCHI FB,et al. Liver autoimmune serology:A consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group[J]. J Hepatol,2004,41(4):677-683.
|
|
[17] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Infectious Diseases,Chinese Medical Association. Consensus on the diagnosis and management of autoimmune hepatitis(2015)[J]. J Clin Hepatol,2016,32(1):9-22.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．自身免疫性肝炎诊断和治疗共识(2015)[J]．临床肝胆病杂志，2016,32(1):9-22.
|
|
[18] LIBERAL R,MIELI-VERGANI G,VERGANI D. Clinical significance of autoantibodies in autoimmune hepatitis[J]. J Autoimmun,2013,46:17-24.
|
|
[19] KIRSTEIN MM,METZLER F,GEIGER E,et al. Prediction of short-and long-term outcome in patients with autoimmune hepatitis[J]. Hepatology,2015,62(5):1524-1535.
|
|
[20] TERZIROLI BERETTA-PICCOLI B,MIELI-VERGANI G,VERGANI D. Serology in autoimmune hepatitis:A clinical-practice approach[J]. Eur J Intern Med,2018,48:35-43.
|
|
[21] MIAO Q,BIAN Z,TANG R,et al. Emperipolesis mediated by CD8 T cells is a characteristic histopathologic feature of autoimmune hepatitis[J]. Clin Rev Allergy Immunol,2015,48(2-3):226-235.
|
|
[22] de BOER YS,van NIEUWKERK CM,WITTE BI,et al. Assessment of the histopathological key features in autoimmune hepatitis[J]. Histopathology,2015,66(3):351-362.
|
|
[23] BALITZER D,SHAFIZADEH N,PETERS MG,et al. Autoimmune hepatitis:Review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria[J].Mod Pathol,2017,30(5):773-783.
|
|
[24] KUMARI N,KATHURIA R,SRIVASTAV A,et al. Significance of histopathological features in differentiating autoimmune liver disease from nonautoimmune chronic liver disease in children[J]. Eur J Gastroenterol Hepatol,2013,25(3):333-337.
|
|
[25] TUCKER SM,JONAS MM,PEREZ-ATAYDE AR. Hyaline droplets in Kupffer cells:A novel diagnostic clue for autoimmune hepatitis[J]. Am J Surg Pathol,2015,39(6):772-778.
|
|
[26] TINIAKOS DG,BRAIN JG,BURY YA. Role of histopathology in autoimmune hepatitis[J]. Dig Dis,2015,33(Suppl 2):53-64.
|
|
[27] GREGORIO GV,PORTMANN B,KARANI J,et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood:A 16-year prospective study[J]. Hepatology,2001,33(3):544-553.
|
|
[28] STRAVITZ RT,LEFKOWITCH JH,FONTANA RJ,et al. Autoimmune acute liver failure:Proposed clinical and histological criteria[J]. Hepatology,2011,53(2):517-526.
|
|
[29] di GIORGIO A,BRAVI M,BONANOMI E,et al. Fulminant hepatic failure of autoimmune aetiology in children[J]. J Pediatr Gastroenterol Nutr,2015,60(2):159-164.
|
|
[30] ARCOS-MACHANCOSES JV,MOLERA BUSOMS C,JULIO TATIS E,et al. Accuracy of the simplified criteria for autoimmune hepatitis in children:Systematic review and decision analysis[J]. J Clin Exp Hepatol,2019,9(2):147-155.
|
|
[31] European Association for the Study of the Liver. EASL clinical practice guidelines:Autoimmune hepatitis[J]. J Hepatol,2015,63(4):971-1004.
|
|
[32] HARRISON L,GLEESON D. Stopping immunosuppressive treatment in autoimmune hepatitis(AIH):Is it justified(and in whom and when)?[J]. Liver Int,2019,39(4):610-620.
|
|
[33] PNIEWSKA A,SOBOLEWSKA-PILARCZYK M,PAWOWSKA M. Evaluation of the effectiveness of treatment with prednisone and azathioprine of autoimmune hepatitis in children[J]. Prz Gastroenterol,2016,11(1):18-23.
|
|
[34] GREGORIO GV,PORTMANN B,KARANI J,et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood:A 16-year prospective study[J]. Hepatology,2001,33(3):544-553.
|
|
[35] GREGORIO GV,PORTMANN B,REID F,et al. Autoimmune hepatitis in childhood:A 20-year experience[J]. Hepatology,1997,25(3):541-547.
|
|
[36] MANNS MP,JAECKEL E,TAUBERT R. Budesonide in autoimmune hepatitis:The right drug at the right time for the right patient[J]. Clin Gastroenterol Hepatol,2018,16(2):186-189.
|
|
[37] PEISELER M,LIEBSCHER T,SEBODE M,et al. Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol,2018,16(2):260-267. e1.
|
|
[38] WOYNAROWSKI M,NEMETH A,BARUCH Y,et al. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents[J]. J Pediatr,2013,163(5):1347-1353. e1.
|
|
[39] MACK CL,ADAMS D,ASSIS DN,et al. Diagnosis and management of autoimmune hepatitis in adults and children:2019practice guidance and guidelines from the American Association for the study of liver diseases[J]. Hepatology,2019.[Epub ahead of print]
|
|
[40] FRANULOVIC'OZ,RAJACIC'N,LESAR T,et al. Cyclosporine induced biochemical remission in childhood autoimmune hepatitis[J]. Coll Antropol,2012,36(3):973-979.
|
|
[41] NASTASIO S,SCIVERES M,MATARAZZO L,et al. Longterm follow-up of children and young adults with autoimmune hepatitis treated with cyclosporine[J]. Dig Liver Dis,2019,51(5):712-718.
|
|
[42] de LEMOS-BONOTTO M,VALLE-TOVO C,COSTABEBER AM,et al. A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment[J]. Eur J Gastroenterol Hepatol,2018,30(2):212-216.
|
|
[43] EFE C,TAII HA,YTTING H,et al. Tacrolimus and mycophenolate mofetil as second-line therapies for pediatric patients with autoimmune hepatitis[J]. Dig Dis Sci,2018,63(5):1348-1354.
|
|
[44] SANTIAGO P,SCHWARTZ I,TAMARIZ L,et al. Systematic review with meta-analysis:Mycophenolate mofetil as a second-line therapy for autoimmune hepatitis[J]. Aliment Pharmacol Ther,2019,49(7):830-839.
|
|
[45] ZIZZO AN,VALENTINO PL,SHAH PS,et al. Second-line agents in pediatric patients with autoimmune hepatitis:A systematic review and meta-analysis[J]. J Pediatr Gastroenterol Nutr,2017,65(1):6-15.
|
|
[46] D'AGOSTINO D,COSTAGUTA A，LVAREZ F. Successful treatment of refractory autoimmune hepatitis with rituximab[J]. Pediatrics,2013,132(2):e526-e530.
|
|
[47] KAVCIC M,FISHER BT,SEIF AE,et al. Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children’s hospitals across the United States[J]. J Pediatr,2013,162(6):1252-1258,1258. e1.
|
|
[48] RAJANAYAGAM J,LEWINDON PJ. Infliximab as rescue therapy in paediatric autoimmune hepatitis[J]. J Hepatol,2013,59(4):908-909.
|
|
[49] AVERBUKH LD,WU GY. Role of biologics in the development of autoimmune hepatitis:A review[J]. J Clin Transl Hepatol,2018,6(4):402-409.
|
|
[50] KUROWSKI J,MELIN-ALDANA H,BASS L,et al. Sirolimus as rescue therapy in pediatric autoimmune hepatitis[J]. J Pediatr Gastroenterol Nutr,2014,58(1):e4-e6.
|
|
[51] NARKEWICZ MR,HORSLEN S,BELLE SH,et al. Prevalence and significance of autoantibodies in children with acute liver failure[J]. J Pediatr Gastroenterol Nutr,2017,64(2):210-217.
|
|
[52] RAMACHANDRAN J,SAJITH KG,PAL S,et al. Clinicopathological profile and management of severe autoimmune hepatitis[J]. Trop Gastroenterol,2014,35(1):25-31.
|
|
[53] MARTIN SR,ALVAREZ F,ANAND R,et al. Outcomes in children who underwent transplantation for autoimmune hepatitis[J]. Liver Transpl,2011,17(4):393-401.
|
|
[54] DENEAU M,JENSEN MK,HOLMEN J,et al. Primary sclerosing cholangitis,autoimmune hepatitis,and overlap in Utah children:Epidemiology and natural history[J]. Hepatology,2013,58(4):1392-1400.
|
|
[55] JOSSEN J,ANNUNZIATO R,KIM HS,et al. Liver transplantation for children with primary sclerosing cholangitis and autoimmune hepatitis:UNOS database analysis[J]. J Pediatr Gastroenterol Nutr,2017,64(4):e83-e87.
|
|
[56] MONTANO-LOZA AJ,BHANJI RA,WASILENKO S,et al.Systematic review:Recurrent autoimmune liver diseases after liver transplantation[J]. Aliment Pharmacol Ther,2017,45(4):485-500.
|
|
[57] PUUSTINEN L,BOYD S,ARKKILA P,et al. Histologic surveillance after liver transplantation due to autoimmune hepatitis[J]. Clin Transplant,2017,31(5):e12936.
|
|
[58] STIRNIMANN G,EBADI M,CZAJA AJ,et al. Recurrent and de novo autoimmune hepatitis[J]. Liver Transpl,2019,25(1):152-166.
|
|
[59] THEOCHARIDOU E,HENEGHAN MA. Con:Steroids should not be withdrawn in transplant recipients with autoimmune hepatitis[J]. Liver Transpl,2018,24(8):1113-1118.
|
|
[60] KALRA A,BURTON JR Jr,FORMAN LM. Pro:Steroids can be withdrawn after transplant in recipients with autoimmune hepatitis[J]. Liver Transpl,2018,24(8):1109-1112.
|
|
[61] DENEAU M,BOOK LS,GUTHERY SL,et al. Outcome after discontinuation of immunosuppression in children with autoimmune hepatitis:A population-based study[J]. J Pediatr,2014,164(4):714-719. e2.
|
|
[62] BOZZINI AB,NEDER L,SILVA CA,et al. Decreased healthrelated quality of life in children and adolescents with autoimmune hepatitis[J]. J Pediatr(Rio J),2019,95(1):87-93.
|
|
[63] van den BRAND FF,van der VEEN KS,de BOER YS,et al.Increased mortality among patients with vs without cirrhosis and autoimmune hepatitis[J]. Clin Gastroenterol Hepatol,2019,17(5):940-947. e2.
|
DownLoad: